NI201600145A - Derivados de nucleósido 4'-sustituidos como inhibidores de la transcriptasa reversa de vih - Google Patents

Derivados de nucleósido 4'-sustituidos como inhibidores de la transcriptasa reversa de vih

Info

Publication number
NI201600145A
NI201600145A NI201600145A NI201600145A NI201600145A NI 201600145 A NI201600145 A NI 201600145A NI 201600145 A NI201600145 A NI 201600145A NI 201600145 A NI201600145 A NI 201600145A NI 201600145 A NI201600145 A NI 201600145A
Authority
NI
Nicaragua
Prior art keywords
reverse transcriptase
derivatives
substituted
nucleoside
inhibitors
Prior art date
Application number
NI201600145A
Other languages
English (en)
Inventor
Girijavallabhan Vinay
B Olsen David
Zhang Zhibo
Fu Jianmin
Tang Bing-Yu
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824598&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201600145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of NI201600145A publication Critical patent/NI201600145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/12—Triazine radicals

Abstract

La presente invención se refiere a derivados de nucleósidos 4' sustituidos de fórmula I y su uso en la inhibición de la transcriptasa reversa de VIH, la profilaxis de la infección por VIH, el tratamiento de la infección por el VIH, y la profilaxis , tratamiento, y retraso en la aparición o pregresión de SIDA y/o ARC.
NI201600145A 2014-03-28 2016-09-26 Derivados de nucleósido 4'-sustituidos como inhibidores de la transcriptasa reversa de vih NI201600145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/074294 WO2015143712A1 (en) 2014-03-28 2014-03-28 4'-substituted nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
NI201600145A true NI201600145A (es) 2016-10-27

Family

ID=52824598

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201600145A NI201600145A (es) 2014-03-28 2016-09-26 Derivados de nucleósido 4'-sustituidos como inhibidores de la transcriptasa reversa de vih

Country Status (41)

Country Link
US (2) US9777035B2 (es)
EP (1) EP3122752B1 (es)
JP (1) JP6182680B2 (es)
KR (1) KR101961009B1 (es)
CN (1) CN106795199B (es)
AP (1) AP2016009482A0 (es)
AR (1) AR099788A1 (es)
AU (2) AU2015236018B2 (es)
CA (1) CA2943792C (es)
CL (1) CL2016002414A1 (es)
CR (1) CR20160451A (es)
CY (1) CY1124829T1 (es)
DK (1) DK3122752T3 (es)
DO (1) DOP2016000265A (es)
EA (1) EA031476B1 (es)
EC (1) ECSP16085206A (es)
ES (1) ES2894228T3 (es)
GE (1) GEP20197009B (es)
GT (1) GT201600201A (es)
HR (1) HRP20211622T1 (es)
HU (1) HUE056913T2 (es)
IL (1) IL247923B (es)
JO (1) JO3636B1 (es)
LT (1) LT3122752T (es)
MA (1) MA39809B1 (es)
MD (1) MD4812C1 (es)
MX (1) MX367058B (es)
MY (1) MY194635A (es)
NI (1) NI201600145A (es)
NZ (1) NZ724343A (es)
PE (1) PE20170197A1 (es)
PH (1) PH12016501897A1 (es)
PL (1) PL3122752T3 (es)
PT (1) PT3122752T (es)
RS (1) RS62418B1 (es)
SG (1) SG11201608031PA (es)
SI (1) SI3122752T1 (es)
SV (1) SV2016005290A (es)
TW (1) TWI660967B (es)
UA (1) UA120758C2 (es)
WO (2) WO2015143712A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41213A (fr) * 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CR20180101A (es) 2015-08-13 2018-04-12 Merck Sharp & Dohme Compuestos di-nucleóticos cíclicos como agonistas de sting
CA2998646C (en) 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物
JOP20190070B1 (ar) 2016-10-04 2023-09-17 Merck Sharp And Dohme Llc مركبات بنزو[b] ثيوفين كناهضات محفزة لبروتين جينات الإنترفيرون
WO2018110591A1 (ja) * 2016-12-13 2018-06-21 ヤマサ醤油株式会社 抗ウイルス活性を有する２'－デオキシ－７－デアザプリンヌクレオシド誘導体
EP3621624B1 (en) 2017-05-12 2023-08-30 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
EP3661499A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND BENZO [B]
JP2020530838A (ja) 2017-08-04 2020-10-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がん治療のためのベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニスト
EP3684782A1 (en) * 2017-09-18 2020-07-29 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US20210060051A1 (en) * 2017-12-27 2021-03-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
MA52189A (fr) 2018-04-03 2021-02-17 Merck Sharp & Dohme Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting
EP3774765A4 (en) 2018-04-03 2021-12-29 Merck Sharp & Dohme Corp. Aza-benzothiophene compounds as sting agonists
CA3105823C (en) * 2018-07-09 2023-07-25 Merck Sharp & Dohme Corp. Enzymatic synthesis of 4'-ethynyl nucleoside analogs
WO2020031131A1 (en) * 2018-08-09 2020-02-13 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
CN113631563A (zh) 2019-01-25 2021-11-09 布朗大学 用于治疗、预防或逆转年龄相关炎症和疾病的组合物和方法
AR118240A1 (es) * 2019-03-06 2021-09-22 GLAXOSMITHKLINE INTELLECTUAL PROPERTY Nº 2 LTD Compuestos útiles en la terapia del vih
CN110054654B (zh) * 2019-05-27 2022-12-27 武汉百科药物开发有限公司 一种地西他滨中间体α-取代脱氧核糖的合成方法
JP2022547558A (ja) * 2019-09-11 2022-11-14 ザ スクリプス リサーチ インスティテュート 抗ウイルスプロドラッグ及びその医薬組成物
WO2021116872A1 (en) * 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
CN112321589B (zh) * 2020-02-18 2022-05-03 山东科巢生物制药有限公司 一种抗病毒药物瑞德西韦及其中间体的合成方法
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法
CN112778310A (zh) * 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN113637041B (zh) * 2020-05-11 2024-02-27 上海科胜药物研发有限公司 一种核糖核苷的制备方法
EP4192474A1 (en) 2020-08-07 2023-06-14 Gilead Sciences, Inc. Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
WO2022074391A1 (en) 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
EP4281081A1 (en) 2021-01-25 2023-11-29 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
US11890297B2 (en) 2021-01-25 2024-02-06 Brii Biosciences, Inc. Combination therapy for HIV with adenosine derivative and capsid inhibitors
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022331233A1 (en) 2021-08-20 2024-02-29 Shionogi & Co., Ltd. Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
WO2023046900A1 (en) 2021-09-23 2023-03-30 Katholieke Universiteit Leuven Ribonucleoside analogues against -sars-cov-2

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0604409B1 (en) 1990-01-11 2004-07-14 Isis Pharmaceuticals, Inc. Oligonucleotide analogs for detecting and modulating rna activity and gene expression
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
KR100412480B1 (ko) 1996-10-16 2003-12-31 아이씨엔 파마슈티컬스, 인코포레이티드 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
WO2000069877A1 (en) 1999-05-12 2000-11-23 Yamasa Corporation 4'-c-ethynyl purine nucleosides
US6831069B2 (en) 1999-08-27 2004-12-14 Ribapharm Inc. Pyrrolo[2,3-d]pyrimidine nucleoside analogs
WO2003062256A1 (en) 2002-01-17 2003-07-31 Ribapharm Inc. 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents
US20040014957A1 (en) 2002-05-24 2004-01-22 Anne Eldrup Oligonucleotides having modified nucleoside units
US20040229839A1 (en) 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
WO2005003047A1 (en) 2003-07-03 2005-01-13 Philips Intellectual Property & Standards Gmbh Pane which can be heated by means of invisible light
CA2502109C (en) 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
AU2007215114A1 (en) 2006-02-14 2007-08-23 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
CN101003550B (zh) * 2006-12-30 2010-05-19 河南省分析测试研究中心 8-卤代腺嘌呤类核苷化合物、合成方法和其药物用途
CA2674589A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
CN100532388C (zh) * 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
CN104262345B (zh) 2008-04-23 2017-06-23 吉利德科学公司 用于抗病毒治疗的1’‑取代的carba‑核苷类似物
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
EP2313102A2 (en) 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0815968D0 (en) 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
CN102216316A (zh) 2008-09-05 2011-10-12 寿制药株式会社 取代胺衍生物及以其为有效成分的药物组合物
NZ617066A (en) 2008-12-23 2015-02-27 Gilead Pharmasset Llc Nucleoside analogs
AU2009329867B2 (en) 2008-12-23 2015-01-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
DE102009000180A1 (de) 2009-01-13 2010-07-15 Evonik Degussa Gmbh Verfahren zur Herstellung von mehrschichtig beschichteten Gummipartikeln und mehrschichtig beschichtete Gummipartikel
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
EA201190178A1 (ru) 2009-03-20 2012-06-29 Алиос Биофарма, Инк. Замещённые нуклеозидные и нуклеотидные аналоги
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
SG181803A1 (en) 2009-12-17 2012-07-30 Merck Sharp & Dohme Aminopyrimidines as syk inhibitors
CA2799926A1 (en) 2010-05-28 2011-12-01 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
ES2709071T3 (es) * 2012-03-13 2019-04-15 Gilead Sciences Inc Análogos de carba-nucleósido 2'-sustituidos para tratamiento antiviral
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
AU2017225090B2 (en) 2018-08-09
CN106795199A (zh) 2017-05-31
DOP2016000265A (es) 2017-04-30
GEP20197009B (en) 2019-08-12
PL3122752T3 (pl) 2022-01-03
WO2015143712A1 (en) 2015-10-01
MX2016012659A (es) 2016-12-14
US9777035B2 (en) 2017-10-03
MD4812C1 (ro) 2023-01-31
CA2943792C (en) 2020-02-25
EA031476B1 (ru) 2019-01-31
AP2016009482A0 (en) 2016-10-31
CN106795199B (zh) 2020-01-10
CL2016002414A1 (es) 2017-05-05
BR112016022438A8 (pt) 2021-06-29
HUE056913T2 (hu) 2022-03-28
PT3122752T (pt) 2021-10-20
AU2017225090A1 (en) 2017-09-28
JO3636B1 (ar) 2020-08-27
ES2894228T3 (es) 2022-02-14
IL247923B (en) 2021-01-31
SV2016005290A (es) 2018-05-03
IL247923A0 (en) 2016-11-30
LT3122752T (lt) 2021-11-10
DK3122752T3 (da) 2021-10-25
AU2015236018A1 (en) 2016-10-06
MD20160117A2 (ro) 2017-02-28
US20150274767A1 (en) 2015-10-01
MA39809B1 (fr) 2021-10-29
CR20160451A (es) 2016-12-06
PH12016501897A1 (en) 2016-12-19
EP3122752A1 (en) 2017-02-01
EA201691931A1 (ru) 2017-02-28
CA2943792A1 (en) 2015-10-01
CY1124829T1 (el) 2022-11-25
RS62418B1 (sr) 2021-10-29
EP3122752B1 (en) 2021-08-25
JP6182680B2 (ja) 2017-08-16
AR099788A1 (es) 2016-08-17
GT201600201A (es) 2018-12-18
MY194635A (en) 2022-12-08
MX367058B (es) 2019-08-02
SI3122752T1 (sl) 2021-11-30
KR20160128437A (ko) 2016-11-07
MD4812B1 (ro) 2022-06-30
US20180002366A1 (en) 2018-01-04
TW201619180A (zh) 2016-06-01
JP2017512797A (ja) 2017-05-25
ECSP16085206A (es) 2017-08-31
SG11201608031PA (en) 2016-10-28
PE20170197A1 (es) 2017-03-22
MA39809A (fr) 2021-04-07
AU2015236018B2 (en) 2017-09-28
TWI660967B (zh) 2019-06-01
NZ724343A (en) 2020-02-28
WO2015148746A1 (en) 2015-10-01
UA120758C2 (uk) 2020-02-10
BR112016022438A2 (pt) 2017-08-15
HRP20211622T1 (hr) 2022-03-04
KR101961009B1 (ko) 2019-03-21

Similar Documents

Publication Publication Date Title
NI201600145A (es) Derivados de nucleósido 4'-sustituidos como inhibidores de la transcriptasa reversa de vih
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CR20150183A (es) Derivados de 5-fenoxi-3h-pirimidin-4-ona y su uso como inhibidores de la transcriptasa inversa del vih
SV2018005629A (es) Compuestos antivirales de fosfodiamida de ester de beta-aminoacido
MX2019007262A (es) Compuestos antivirales de bencilamina fosfodiamida.
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
MX2018003212A (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
HN2012002039A (es) Inhibidores no nucleosidicos de la transcriptasa inversa
BR112016022722A2 (pt) pró-fármacos de inibidores da transcriptase reversa de hiv
DOP2018000183A (es) Compuesto útil para el tratamiento y la profilaxis de vih y sida y sus usos
WO2015017393A3 (en) Piperazine derivatives as hiv protease inhibitors
MX2016009064A (es) Derivados de hidroxi formamida y su uso.